TY - JOUR T1 - Mendelian randomization of dyslipidemia on cognitive impairment among older Americans JF - medRxiv DO - 10.1101/2020.10.20.20216036 SP - 2020.10.20.20216036 AU - Mingzhou Fu AU - Kelly M. Bakulski AU - Cesar Higgins AU - Erin B. Ware Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/21/2020.10.20.20216036.abstract N2 - Background Altered lipid metabolism may be a risk factor for dementia, and blood cholesterol level has a strong genetic component. We tested the hypothesis that dyslipidemia (either low levels of high-density lipoprotein cholesterol (HDL-C) or high total cholesterol) is associated with cognitive status and domains, and assessed inferred causality using genetic predisposition to dyslipidemia as an instrumental variable.Methods Using data from European and African genetic ancestry participants in the Health and Retirement Study, we selected observations at the first non-missing biomarker assessment (waves 2006 to 2012). Cognition domains were assessed using episodic memory, mental status, and vocabulary tests. Overall cognitive status was categorized in three levels (normal, cognitive impairment non-dementia, dementia). Based on 2018 clinical guidelines, we compared low HDL-C or high total cholesterol to normal levels. Polygenic scores for dyslipidemia were used as instrumental variables in a Mendelian randomization framework. Multivariable logistic regressions and Wald-type ratio estimators were used to examine associations.Results Among European ancestry participants (n = 8781), at risk HDL-C levels were associated with higher odds of cognitive impairment (OR = 1.20, 95%CI: 1.03, 1.40) and worse episodic memory, specifically. Using cumulative genetic risk for HDL-C levels as a valid instrumental variable, a significant causal estimate was observed between at risk low HDL-C levels and higher odds of dementia (OR = 2.15, 95%CI: 1.16, 3.99). No significant associations were observed between total cholesterol levels and cognitive status. No significant associations were observed in the African ancestry sample (n = 2101).Conclusion Our study demonstrates low blood HDL-C is a potential causal risk factor for impaired cognition during aging in non-Hispanic whites of European ancestry. Dyslipidemia can be modified by changing diets, health behaviors, and therapeutic strategies, which can improve cognitive aging. Studies on low density lipoprotein cholesterol, the timing of cholesterol effects on cognition, and larger studies in non-European ancestries are needed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll authors were supported by grants from the National Institute on Aging (R01 AG055406 and R01 AG067592). Dr. Bakulski was supported by grants from the National Institute for Environmental Health Sciences and the National Institute for Minority Health and Health Disparities (R01 ES025531; R01 ES025574; and R01 MD013299). Dr. Ware was supported by a grant from the National Institute on Aging (R01 AG055654). This work was supported by the Michigan Center for the Demography of Aging (P30 AG012846) and the Michigan Alzheimer Disease Center (P30 AG053760). The funders did not have any role in the design, analysis, interpretation, or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:e Health and Retirement Study is sponsored by the National Institute on Aging (NIA U01AG009740) and is conducted by the University of Michigan, where written informed consent was approved by the Institutional Review Board. This analysis was exempt and not regulated as determined by the Institutional Review Board at the University of Michigan (HUM00128220).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Health and Retirement Data are publicly available through the HRS website (https://hrs.isr.umich.edu/about). Raw genetic data on unrelated individuals, both genotyped and imputed to the 1000 Genomes Project, is available from the National Center for Biotechnology Information database of genotypes and phenotypes (dbGaP Study Accession: phs000428.v2.p2). https://hrs.isr.umich.edu/about https://www.ncbi.nlm.nih.gov/gap/ BMIbody mass indexCIconfidence intervalsCINDcognitive impairment-non dementiaGWASgenome-wide association studyHDL-Chigh-density lipoprotein cholesterolHRSHealth and Retirement StudyORodds ratiosPCprincipal componentPGSpolygenic scoreSNPsingle nucleotide polymorphismsTCtotal cholesterol ER -